Skip to content
Screener

Evommune EVMN Q3 2026 earnings

Reported November 12, 2026 · After market close

EPS-$0.85Miss by $0.02
Revenue estimate$428.6K
EPS estimate-$0.83
“We have built a portfolio of differentiated immunology assets spanning biologics and small molecules, each aimed at a distinct upstream driver of chronic inflammation. The in-licensing of EVO570 expands our reach into T- and B-cell-driven autoimmune diseases, while the EADV data strengthen our conviction that EVO301 has the potential to become a foundational therapy in atopic dermatitis, if approved”
Luis Pe

Next report

Date not yet announced

FAQ

When did Evommune report Q3 2026 earnings?
Evommune (EVMN) reported Q3 2026 earnings on November 12, 2026 after market close.
What were Evommune's Q3 2026 revenue and EPS?
Evommune reported eps of $-0.85 for Q3 2026.
Did Evommune beat estimates in Q3 2026?
EPS missed the consensus estimate of $-0.83 by $0.02.
How did Evommune's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 89.5% from $-8.07.
Where can I find Evommune's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-458329) and the 10-Q periodic report (0001193125-26-458385) directly on SEC EDGAR. The filing index links above go to sec.gov.